Advances in Radioembolization for Liver Cancer

Area of Science:

• Oncology
• Radiology
• Biomedical Engineering

Background:

• Radioembolization, particularly with yttrium-90 microspheres, is a well-established treatment for primary and metastatic liver cancers.
• Advancements in patient selection and dosimetry have improved its efficacy, establishing it as a frontline therapy in various clinical settings.
• Current limitations hinder the full potential of radioembolization for liver cancers and other solid tumors.

Purpose of the Study:

• To review preclinical advances in image-guided delivery of cancer therapeutics aimed at enhancing radioembolization.
• To explore novel strategies including codelivery of agents and alternative radionuclides for improved cancer treatment.

Main Methods:

• Review of preclinical research on image-guided delivery systems for cancer therapeutics.
• Investigation of codelivery strategies involving nanophotosensitizers, chemotherapeutics, immune adjuvants, and photothermal agents.
• Exploration of alternative radionuclides, such as alpha emitters, for local delivery via image guidance.

Main Results:

• Preclinical studies demonstrate potential for image-guided delivery of novel agents to improve radioembolization.
• Codelivery of various therapeutic agents shows promise in harnessing additional tumoricidal mechanisms.
• Alternative radionuclides offer new possibilities for targeted radionuclide therapy.

Conclusions:

• Preclinical advances in image-guided delivery and novel agents are poised to expand the applications of radioembolization.
• Future research focusing on these innovative approaches may overcome existing limitations in liver cancer and solid tumor treatment.
• Image-guided delivery of radionuclides and combination therapies represent a promising frontier in cancer therapeutics.